Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531242 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Not yet
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT03531242 is a Phase 2 study that has not yet begun recruiting, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 500 participants.
The verdict
NCT03531242, a Phase 2 study, has not yet begun recruiting, sponsored by U.S. Army Medical Research and Development Command.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, C-84, TSI-GSD 205, Lot 7, Run 1, and collect data on the incidence of occupational VEE infection in vaccinated personnel.
Interventions
- BIOLOGICAL 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-06 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03531242
The ClinicalTrials.gov registry entry for NCT03531242 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1 is the first listed.
NCT03531242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03531242 about?
NCT03531242 is a clinical study titled "Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults". The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, C-84, TSI-GSD 205, Lot 7, Run 1, and collect data on the incidence of occupational VEE infection in vaccinated personnel.
What is the current status of trial NCT03531242?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2021-06. Estimated completion is 2024-12.
What interventions are being tested in trial NCT03531242?
The interventions under investigation include: 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03531242?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.